Periplogenin is a compound extracted from cortex periplocae. In the monomers' screening for inhibiting nasopharyngeal carcinoma, we found that periplogenin can inhibit nasopharyngeal carcinoma; however, its mechanism is still unclear. In this study, the chemical structure of periplogenin was uploaded to the PubChem database in order to obtain the target of periplogenin. The NPC's differential genes were obtained by analyzing the nasopharyngeal carcinoma data in the GEO database by R software. The common target of periplogenin and nasopharyngeal carcinoma was obtained through Cytoscape. Through R software analysis, ALB, epidermal growth factor receptor (EGFR), MAPK1, ESR1, MAPK8, SRC, CASP3, HSP90AA1, AR, MAPK14 may be the main targets of periplogenin in NPC. Through go enrichment analysis, it was found that periplogenin acted mainly on nasopharyngeal carcinoma through response to steroid metabolic process, cellular response to steroid hormone stimulus, hormone-mediated, and steroid hormone signaling pathway. After enrichment analysis on the Kyoto Encyclopedia of Genes and Genomes pathway, it was found that periplocan may inhibit NPC through the MAPK signaling pathway (the main signaling pathway), and the signaling pathway of proteoglycans in cancer, and the PI3K/AKT signaling pathway as well. In this study, we also carried out the experimental study of vitamin E together with periplogenin self-assembled nano-prodrugs in the treatment of NPC, and the results showed that tumor weight of PBS group was 0.531±0.039 g, while that of PPG group and MPSSV-NPs group was 0.258±0.059 g and 0.169±0.033 g, respectively, which was lower than PBS group. And the tumor inhibition rate of MPSSV-NPs was 69.41%, which was significantly higher than that of the PPG group (51.38%). This study demonstrated the mechanism of inhibition of nasopharyngeal carcinoma (NPC) by the monomer of periplogenin based on network pharmacology. We preliminarily confirmed that vitamin E coupled with a periplogenin self-assembled nano-prodrug has obvious effect in treating nasopharyngeal carcinoma.

中文翻译：

---

基于网络药理学的Periplogenin作用于鼻咽癌的作用机理和维生素E结合Periplogenin自组装纳米药物治疗鼻咽癌的实验研究。

Periplogenin是从皮质皮层中提取的化合物。在抑制鼻咽癌的单体筛选中，我们发现periplogenin可以抑制鼻咽癌。但是，其机制仍不清楚。在这项研究中，periplogenin的化学结构被上载到PubChem数据库中，以获得periplogenin的目标。NPC的差异基因是通过R软件分析GEO数据库中的鼻咽癌数据而获得的。通过Cytoscape获得了骨膜激蛋白和鼻咽癌的共同靶标。通过R软件分析，ALB，表皮生长因子受体（EGFR），MAPK1，ESR1，MAPK8，SRC，CASP3，HSP90AA1，AR，MAPK14可能是NPC中骨成膜激素的主要靶标。通过去富集分析，研究发现，骨膜激蛋白主要通过对类固醇代谢过程的反应，对类固醇激素刺激的细胞反应，激素介导的和类固醇激素信号传导途径而主要作用于鼻咽癌。在对《京都议定书》的基因和基因组百科全书进行富集分析后，发现高果胶可能通过MAPK信号传导途径（主要的信号传导途径），蛋白聚糖的信号传导途径以及癌症中的PI3K / AKT信号传导途径抑制NPC。好。在这项研究中，我们还进行了维生素E结合骨胶原蛋白自组装纳米前药治疗NPC的实验研究，结果表明PBS组的肿瘤重量为0.531±0.039 g，而PPG组的肿瘤重量为0.531±0.039 g。 MPSSV-NPs组分别为0.258±0.059 g和0.169±0.033 g，低于PBS组。MPSSV-NPs的抑瘤率为69.41％，明显高于PPG组（51.38％）。这项研究基于网络药理学证明了periplogenin单体抑制鼻咽癌（NPC）的机制。我们初步证实，维生素E结合骨膜激蛋白自组装的纳米前药对鼻咽癌有明显的治疗作用。